Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR)

Schroeder, Marion LU ; Westborg, Inger and Lövestam Adrian, Monica LU (2020) In Acta Ophthalmologica 98(3). p.274-278
Abstract

Purpose: To analyse characteristics from the SMR to explore the risk factors for visual acuity (VA) below ≤ 35 letters of the Early Treatment Diabetic Retinopathy Study (ETDRS) due to nAMD during a two-year follow-up. Methods: This study evaluates 6142 treatment-naïve eyes, with focus on a subgroup of 780 eyes with final VA outcome of ≤ 35 letters, regarding differences of baseline characteristics, change of VA, number of injections and choice of drug to predict visual outcome. Results: Patients with final VA ≤ 35 letters were older; p < 0.0001, and received fewer injections, 6.2 ± 3.8 vs. 8.7 ± 5.4; p < 0.00001. Only 4% of all patients with ≥ 70 letters baseline VA decreased to a final VA of ≤ 35 letters. The two groups with a... (More)

Purpose: To analyse characteristics from the SMR to explore the risk factors for visual acuity (VA) below ≤ 35 letters of the Early Treatment Diabetic Retinopathy Study (ETDRS) due to nAMD during a two-year follow-up. Methods: This study evaluates 6142 treatment-naïve eyes, with focus on a subgroup of 780 eyes with final VA outcome of ≤ 35 letters, regarding differences of baseline characteristics, change of VA, number of injections and choice of drug to predict visual outcome. Results: Patients with final VA ≤ 35 letters were older; p < 0.0001, and received fewer injections, 6.2 ± 3.8 vs. 8.7 ± 5.4; p < 0.00001. Only 4% of all patients with ≥ 70 letters baseline VA decreased to a final VA of ≤ 35 letters. The two groups with a final VA of ≤ 35 letters and VA > 35 letters presented the following baseline lesion locations; p = 0.001; 61% vs. 57% subfoveal, 18% vs. 21% juxtafoveal and 4% vs. 6% extrafoveal. Lesion size, in the group with final VA ≤ 35 letters, was 2805 ± 2093 μm vs. 2440 ± 1637 μm in the group with a VA of > 35 letters; p = 0.005. A logistic regression analysis including baseline VA, best- or worse-seeing eye, age, membrane size, membrane location, symptom duration showed VA; p = < 0.0001, best- or worse-seeing eye; p = 0.026, age; p = < 0.0001, and membrane size; p = 0.002 to predict a decline of VA within 2 years. Conclusions: In eyes treated for wet AMD and studied for 2 years, 12.7% of eyes declined to a final VA of ≤ 35 letters. Visual acuity, worse-seeing eye treated, age and membrane size turned out as the baseline characteristics that had significantly influenced visual decline to ≤ 35 letters during the two-year follow-up.

(Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
aflibercept, bevacizumab, neovascular age-related macular degeneration, ranibizumab, Swedish Macula Registry
in
Acta Ophthalmologica
volume
98
issue
3
pages
5 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:85073780254
  • pmid:31517440
ISSN
1755-375X
DOI
10.1111/aos.14239
language
English
LU publication?
yes
id
7c088014-2f2c-429f-a9b0-d2b2d9d37a5f
date added to LUP
2019-11-01 10:48:51
date last changed
2022-08-11 01:38:49
@article{7c088014-2f2c-429f-a9b0-d2b2d9d37a5f,
  abstract     = {{<p>Purpose: To analyse characteristics from the SMR to explore the risk factors for visual acuity (VA) below ≤ 35 letters of the Early Treatment Diabetic Retinopathy Study (ETDRS) due to nAMD during a two-year follow-up. Methods: This study evaluates 6142 treatment-naïve eyes, with focus on a subgroup of 780 eyes with final VA outcome of ≤ 35 letters, regarding differences of baseline characteristics, change of VA, number of injections and choice of drug to predict visual outcome. Results: Patients with final VA ≤ 35 letters were older; p &lt; 0.0001, and received fewer injections, 6.2 ± 3.8 vs. 8.7 ± 5.4; p &lt; 0.00001. Only 4% of all patients with ≥ 70 letters baseline VA decreased to a final VA of ≤ 35 letters. The two groups with a final VA of ≤ 35 letters and VA &gt; 35 letters presented the following baseline lesion locations; p = 0.001; 61% vs. 57% subfoveal, 18% vs. 21% juxtafoveal and 4% vs. 6% extrafoveal. Lesion size, in the group with final VA ≤ 35 letters, was 2805 ± 2093 μm vs. 2440 ± 1637 μm in the group with a VA of &gt; 35 letters; p = 0.005. A logistic regression analysis including baseline VA, best- or worse-seeing eye, age, membrane size, membrane location, symptom duration showed VA; p = &lt; 0.0001, best- or worse-seeing eye; p = 0.026, age; p = &lt; 0.0001, and membrane size; p = 0.002 to predict a decline of VA within 2 years. Conclusions: In eyes treated for wet AMD and studied for 2 years, 12.7% of eyes declined to a final VA of ≤ 35 letters. Visual acuity, worse-seeing eye treated, age and membrane size turned out as the baseline characteristics that had significantly influenced visual decline to ≤ 35 letters during the two-year follow-up.</p>}},
  author       = {{Schroeder, Marion and Westborg, Inger and Lövestam Adrian, Monica}},
  issn         = {{1755-375X}},
  keywords     = {{aflibercept; bevacizumab; neovascular age-related macular degeneration; ranibizumab; Swedish Macula Registry}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{274--278}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Acta Ophthalmologica}},
  title        = {{Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR)}},
  url          = {{http://dx.doi.org/10.1111/aos.14239}},
  doi          = {{10.1111/aos.14239}},
  volume       = {{98}},
  year         = {{2020}},
}